AYTU BIOPHARMA, INC Gain (Loss) on Extinguishment of Debt
AYTU BIOPHARMA, INC (AYTU) reported Gain (Loss) on Extinguishment of Debt of $0 for the 12-month period ending 2025-06-30, per its 10-K filed 2025-09-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2025-09-23
- AYTU BIOPHARMA, INC gain (loss) on extinguishment of debt for the quarter ending 2022-06-30 was $0.00.
- AYTU BIOPHARMA, INC gain (loss) on extinguishment of debt for the quarter ending 2022-03-31 was $169.00K.
- AYTU BIOPHARMA, INC gain (loss) on extinguishment of debt for the quarter ending 2021-06-30 was -$1.31M.
- AYTU BIOPHARMA, INC gain (loss) on extinguishment of debt for the quarter ending 2021-03-31 was $0.00.
- AYTU BIOPHARMA, INC gain (loss) on extinguishment of debt for fiscal 2025 was $0.00.
- AYTU BIOPHARMA, INC gain (loss) on extinguishment of debt for fiscal 2024 was -$594.00K.
- AYTU BIOPHARMA, INC gain (loss) on extinguishment of debt for fiscal 2022 was $169.00K.
- AYTU BIOPHARMA, INC gain (loss) on extinguishment of debt for fiscal 2021 was -$1.57M.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month | Gain (Loss) on Extinguishment of Debt 12 month as first filed |
|---|---|---|---|---|---|
| 2025-06-30 | $0.00 10-K · filed 2025-09-23 | ||||
| 2024-06-30 | -$594.00K 10-K · filed 2025-09-23 | ||||
| 2022-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-12 | $169.00K derived: sum of 2 quarters · filed 2023-10-12 | $169.00K 10-K · filed 2023-10-12 | ||
| 2022-03-31 | $169.00K 10-Q · filed 2023-05-11 | $169.00K 10-Q · filed 2023-05-11 | |||
| 2021-06-30 | -$1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27 | -$1.31M derived: sum of 2 quarters · filed 2022-09-27 | -$1.57M derived: sum of 3 quarters · filed 2022-09-27 | -$1.57M 10-K · filed 2022-09-27 | |
| 2021-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-16 | -$258.00K derived: sum of 2 quarters · filed 2022-05-16 | -$258.00K 10-Q · filed 2022-05-16 | ||
| 2020-12-31 | -$258.00K 10-Q · filed 2022-02-14 | -$258.00K 10-Q · filed 2022-02-14 | |||
| 2020-06-30 | -$316.00K 10-K · filed 2021-09-28 | -$315.73K 10-K · filed 2020-10-06 | |||
| 2019-06-30 | $0.00 10-K · filed 2020-10-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |